Molecular and Genetic Analysis of Collagen Type IV Mutant Mouse Models of Spontaneous Intracerebral Hemorrhage Identify Mechanisms for Stroke Prevention

Running title: Jeanne et al.; Hemorrhagic stroke caused by collagen IV mutations

Marion Jeanne, PhD, Jeff Jorgensen, BSc; Douglas B. Gould, PhD

Depts of Ophthalmology and Anatomy, Institute for Human Genetics, University of California, San Francisco (UCSF), San Francisco, CA

Address for Correspondence:
Douglas B. Gould, PhD
University of California, San Francisco
10 Koret Way (K235)
San Francisco, CA 94143-0730
Tel: 415-476-3592
Fax: 415-476-0336
E-mail: GouldD@vision.ucsf.edu

Journal Subject Code: Basic science research:[130] Animal models of human disease
Abstract

**Background**—Collagen type IV alpha 1 (COL4A1) and alpha 2 (COL4A2) form heterotrimers critical for vascular basement membrane stability and function. Patients with *COL4A1* or *COL4A2* mutations suffer from diverse cerebrovascular diseases including cerebral microbleeds, porencephaly and fatal intracerebral hemorrhage (ICH). However, the pathogenic mechanisms remain unknown and there is a lack of effective treatment.

**Methods and Results**—Using *Col4a1* and *Col4a2* mutant mouse models, we investigated the genetic complexity and cellular mechanisms underlying the disease. We found that *Col4a1* mutations cause abnormal vascular development, which triggers small vessel disease, recurrent hemorrhagic strokes and age-related macro-angiopathy. We showed that allelic heterogeneity, genetic context and environmental factors, such as acute exercise or anticoagulant medication, modulated disease severity and contributed to phenotypic heterogeneity. We found that intracellular accumulation of mutant collagen in vascular endothelial cells and pericytes was a key triggering factor of ICH. Finally, we showed that treatment of mutant mice with a FDA-approved chemical chaperone resulted in a decreased collagen intracellular accumulation and a significant reduction of ICH severity.

**Conclusions**—Our data are the first to show therapeutic prevention *in vivo* of ICH due to *Col4a1* mutation, and imply that a mechanism-based therapy promoting protein folding might also prevent ICH in patients with *COL4A1* and *COL4A2* mutations.

**Key words:** cerebrovascular disorders, collagen, genetics, hemorrhage, stroke, Col4a1, Col4a2, angiogenesis, intracerebral hemorrhage
Introduction

Strokes cause a death every four minutes in the United States, representing the fourth leading cause of death and a major cause of long-term disability. Intracerebral hemorrhages (ICHs) are the most fatal form of stroke. Lack of effective treatment options and poor clinical outcomes for ICH patients suggest that prevention is paramount for reducing the tremendous personal and societal burden. Development of preventive strategies relies on understanding environmental and genetic factors that contribute to ICH risk. Mutations in the genes encoding collagen type IV alpha 1 (COL4A1) and alpha 2 (COL4A2) cause highly penetrant cerebrovascular disease with variable expressivity. COL4A1 mutations are a significant cause of porencephaly and pediatric ICH, which are associated with particularly poor outcomes including cerebral palsy, intellectual disabilities, developmental and behavioral disorders, and epilepsy. COL4A1 and COL4A2 mutations also cause spontaneous ICHs in adults. Thus, COL4A1 and COL4A2 mutations are important causes of highly penetrant perinatal ICH and may play a substantial role in age-related cerebrovascular diseases.

COL4A1 and COL4A2 are extracellular matrix molecules that form a network integral to basement membranes. They are co-translationally translocated into the endoplasmic reticulum (ER) where they assemble into heterotrimers composed of one COL4A2 and two COL4A1 molecules. Each protein has a large triple-helical domain flanked by the 7S and non-collagenous (NC1) domains at the amino and carboxy terminus, respectively. The globular NC1 domains are responsible for initiating heterotrimer assembly, which proceeds by the progressive inter-winding of the triple-helical domains. Triple-helical domains are characterized by repeated Gly-Xaa-Yaa motifs (Xaa and Yaa represent variable amino acids) and form greater than 80% of the proteins. Like in other collagens, glycine missense mutations...
are the most common type of mutation and, in vitro, the primary consequence appears to be impaired heterotrimer biosynthesis. How this may contribute to ICH in vivo remains unknown. Pathogenesis could involve toxic intracellular heterotrimer accumulation and/or extracellular deficiency of normal collagen and/or extracellular presence of mutant collagen.

Our objectives were to identify the molecular and cellular events that occur in the neurovascular unit leading to ICH in Col4a1 mutant mice and to identify preventative therapeutics that target these events. We investigated the timing and location of pathogenesis and potential roles of intracellular and extracellular insults using multiple mouse models. Importantly, we identified modifiable ICH risk factors and a pharmacologic intervention that reduced ICH in vivo. These data provide proof-of-principle for mechanism-based interventions to reduce, delay or prevent ICH in patients with COL4A1 and COL4A2 mutations.

Materials and Methods

Animals

Procedures were in accordance with Institutional Animal Care and Use Committee guidelines. Col4a1 and Col4a2 mutant mice were described previously. Each strain was iteratively crossed to C57BL/6J (B6) mice for at least five generations. CAST/EiJ (CAST) and 129S6/SvEvTac (129) breeders were mated with B6 mice to produce CASTB6F1 and 129B6F1 mice respectively. The Col4a1Flex41 conditional mutant mouse was produced by InGenious Targeting Laboratory (Stony Brook, NY). Rosa26-CreER were used for ubiquitous inducible CRE expression. Tie2-Cre, Pdgfrb-Cre and Gfap-Cre were used for cell-type specific CRE expression. We used ROSA26tm14(CAG-tdTomato) reporter mice to validate CRE-mediated recombination. Unless specified, all mutant mice were heterozygous and both sexes were used.
In vivo procedures

CRE was activated with tamoxifen (10 mg.mL⁻¹, Sigma-Aldrich, St Louis, MO). Pregnant females received one intraperitoneal tamoxifen injection (2 mg) mixed with progesterone (1 mg, Sigma-Aldrich, St Louis, MO). Pups received one intragastric tamoxifen injection (50 μg) for three consecutive days, and 3-week-old mice received one intraperitoneal tamoxifen injection (2 mg) for two consecutive days.

Virgin 3-month-old females were exercised on a horizontal treadmill (Exer 3/6, Columbus Instruments, Columbus, OH) for five sessions. Each session included a 2-minute acclimation period (speed: 0 m.min⁻¹), 8-minute warm-up (3 min at 6 m.min⁻¹, 3 min at 9 m.min⁻¹, 2 min at 12 m.min⁻¹) and five 1-min sprints (1 min at 15 m.min⁻¹ followed by 1 min rest at 0 m.min⁻¹). Sessions were performed 5 days apart and animals were sacrificed 12 days after the last session.

Mice received Warfarin (Warfarin Sodium Tablets, Amneal Pharmaceuticals, Bridgewater, NJ) via drinking water at the estimated dose of 0.4 mg.kg⁻¹ per day (2.5 mg dissolved in 800mL water) for 4 days, water without Warfarin for 2 days, then water with Warfarin for 3 days. Because two mutant mice died, treatment was discontinued and remaining animals were sacrificed 11 days later.

Mice received sodium 4-phenylbutyrate (4PBA, Enzo Life Sciences Inc., Farmingdale, NY) diluted in Phosphate Buffered Saline (PBS) by injection. Pups received intragastric injection of 0.1 mg 4PBA at postnatal day 1 (P1), P3, P5 and P7, then intraperitoneal injection of 0.5 mg 4PBA at P10, P12, P14, P16, P18 and P20, and finally received intraperitoneal injection of 1.0 mg 4PBA at P23 and P26. Mice were sacrificed at 1 month of age.

Retinal fluorescein angiography was performed using a Micron III (Phoenix Research
Labs Inc., Pleasanton, CA). One-month old mice were anesthetized with Ketamine (100 mg.kg⁻¹) and Xylazine (10 mg.kg⁻¹) and received an intraperitoneal 20 μL Fluorescein Sodium injection (25 mg.mL⁻¹ in PBS, Altaire Pharmaceuticals Inc., Riverhead, NY).

**Histology and immunofluorescence labeling**

Anesthetized mice were transcardially perfused with saline followed by 4% paraformaldehyde (PFA) in PBS. Brains were post-fixed in 4% PFA for 16 hours, cryo-protected in 30% sucrose/PBS and embedded in OCT (Sakura Finetek, Torrance, CA). For ICH quantification, coronal cryo-sections (35 μm) regularly spaced along the rostro-caudal axis were stained with Prussian blue/Fast red. Images were acquired using a SteREO Discovery.V8 microscope, an AxioCam ICc3 camera and AxioVision 4.6 software (Carl Zeiss Microscopy, LLC, Germany). On each section, the percentage of brain area with Prussian blue staining was calculated using ImageJ software (NIH). Hemorrhage severity was expressed as the average percentage of hemosiderin surface area on 27 sections for each brain. Trichrome staining was performed on 5 μm paraffin sections according to the manufacturer protocol (One step Trichrome Blue/Red Stain kit, American Mastertech Scientific Inc., Lodi, CA).

For the investigation of blood-brain-barrier integrity, 10 mL of biotin (EZ-link sulfo-NHS-Biotin, 0.5 mg.mL⁻¹ in PBS, Thermo Scientific, Waltham, MA) was transcardially perfused, after washing with saline and before fixation with 4% PFA. Coronal cryo-sections were fixed 15 min in 4% PFA and labeled with Streptavidin Alexa Fluor® 488 (2 pg.μL⁻¹, Invitrogen-Molecular Probes, Carlsbad, CA). Alternatively, a 2% Evans blue solution in saline (4 mL.kg⁻¹) was injected intraperitoneally and allowed to circulate 24 hours.

Embryos were fixed 1 hour in cold methanol, cryo-protected in 30% sucrose/PBS and cryo-sectioned (20 μm). For embryonic angiogenesis, hindbrains were fixed 1 hour in 4% PFA
before flat-mounting. For retinal analysis, enucleated eyes were fixed 16 hours in 4% PFA and
dissected retinas were flat mounted. Cultured primary fibroblasts were fixed 15 min in 4% PFA
and permeabilized in PBS/0.1% Triton X-100 before immunolabelling. Cryo-sections were post-
fixed in 4% PFA for 15 min prior to immunolabelling. All specimens were blocked in PBS with
10% normal donkey serum, 1% bovine serum albumin and 0.3% Triton X-100. Primary
antibodies: rat CD31 (1:200, BD Biosciences, San Jose, CA), goat type IV collagen (1:200,
Southern Biotech, Birmingham, AL), rat COL4A1 (1:100, H11 clone, Shigei Medical Research
Institute, Japan26), rabbit ZO-1 (1:100, Abcam, Cambridge, UK), rabbit Claudin5 (1:100,
Invitrogen, Carlsbad, CA) and mouse HSP47 (1:500, M16.10A1 clone, Stressgen
Biotechnologies, San Diego, CA) were incubated 3 hours at room temperature for cryo-sections
or for 48 hours at 4°C for flatmounts. After 3 washes in PBS/0.1% Triton X-100, secondary
antibodies Alexa Fluor® 488 or 594 (1:500 dilution, Invitrogen-Molecular Probes, Carlsbad, CA)
were incubated 1 hour for sections or 24 hours for flatmounts. After 3 washes, coverslips were
mounted using Mowiol with DAPI (2 μg.mL⁻¹). A Zeiss AxioImager M.1 and a Zeiss LSM700
with plan-Apochromat objectives (63x/1.4 oil-immersion or 20x/0.8) were used for fluorescence
microscopy, with an AxioCam MRm camera and AxioVision and ZEN softwares (Carl Zeiss
Microscopy, LLC, Germany). Embryonic vascular plexus density quantifications were
performed using ImageJ. Vein branch point quantifications were realized by averaging numbers
of at least three primary veins per retina.

**Western Blot analysis**

Mouse embryonic fibroblasts were cultured in DMEM with 10% fetal bovine serum, 2 mM L-
glutamine, 0.2 mM penicillin/streptomycin at 37°C in 5% CO₂. At confluence, cells were serum-
deprived and treated with 50 μg.mL⁻¹ of ascorbic acid for 16 hours. Proteins were separated on 4-
15% gradient SDS-PAGE gels (Bio-Rad Laboratories Inc., Hercules, CA). Membranes were blocked 16 hours in Tris Buffered Saline/0.1% Tween-20 (TBS-T) with 5% non-fat milk, then incubated 16 hours with primary antibodies: rat COL4A1 (1:200, H11 clone, Shigei Medical Research Institute, Japan\textsuperscript{26}), tubulin (1:10000, T6557, Sigma-Aldrich, St Louis, MO), laminin (1+2) (1:2000, ab7463, Abcam, Cambridge, UK). After 3 washes in TBS-T, membranes were incubated 1 hour with horseradish peroxidase-conjugated secondary antibodies (1:10000, Jackson ImmunoResearch, West Grove, PA). After 3 washes, SuperSignal West Pico Chemiluminescent substrate (Thermo Scientific, Waltham, MA) was used according to manufacturer's instructions.

**Statistical Analysis**

Normality was assessed using Kolmogorov-Smirnov and Shapiro-Wilk tests. Two-group comparisons were carried out using Student's t-test. Multiple group comparisons were performed using ANOVA followed by Tukey post-test or Kruskal-Wallis test followed by Dunn’s post-test for normally and not normally distributed variables, respectively. p values < 0.05 were considered statistically significant. Data are presented as mean + or ± standard deviation.

**Results**

**Pathogenesis occurs in distinct stages**

Col4a1\textsuperscript{ex41} is a splice–site mutation that skips exon 41 in the triple-helical domain of murine Col4a1\textsuperscript{3, 17, 27}. Col4a1\textsuperscript{ex41/ex41} mice die during embryogenesis and Col4a1\textsuperscript{+/ex41} mice exhibit embryonic growth retardation and reduced postnatal viability (**Supplemental Figure 1**). Modeling patients with COL4A1 mutations, surviving Col4a1\textsuperscript{+/ex41} mice have multi-system disorders, including fully penetrant cerebrovascular disease presenting as porencephaly, prenatal,
perinatal and recurrent multi-focal ICHs\textsuperscript{17,27}. At embryonic day (E) 10.5 we observed irregularly shaped and enlarged blood vessels, and multifocal intraparenchymal and intraventricular hemorrhages (Figure 1A). Analysis of cerebral angiogenesis at E12.5 revealed increased vessel density and tortuosity in $Col4a1^{+/loxP}$ hindbrains (Figure 1B). Mature retinal vasculature showed similar defects including persistent hyaloid vessels and abnormal crossing of excessively branched, tortuous arteries and veins with irregular diameters (Figure 1C). We also detected tortuous cerebral arteries, veins and capillaries in adult $Col4a1^{+/loxP}$ mice (Figure 1D). Cerebral and retinal vessels were not permeable to biotin, Evans blue dye or sodium fluorescein and tight junction proteins were normally expressed during brain development indicating that the blood-brain and blood-retinal barriers are intact (Figure 1D and Supplemental Figure 2).

At birth, $Col4a1^{+/loxP}$ pups had numerous macroscopic subcutaneous hematomas, extra-axial hemorrhages and frequent intraparenchymal hemorrhages (Supplemental Figure 1C). Consistent with highly penetrant intraventricular hemorrhages, 80\% of $Col4a1^{+/loxP}$ mice had porencephaly (Figure 2A). ICH was completely penetrant, however, the location and character of the lesions changed with time suggesting different stages of pathology. At 1-month, $Col4a1^{+/loxP}$ mice had small vessel disease, with multiple, small hemosiderin deposits throughout the cortex, cerebral nuclei, brain stem and cerebellum. By 3-months, these were cleared but fewer and larger hemorrhages appeared in the basal ganglia. Reduced hemoglobin level and age-dependent hemosiderin accumulation indicated recurring ICHs (Figure 2A and Supplemental Figure 3). Importantly, cerebral macro-angiopathy with fibrotic vessel wall thickening and thrombus formation appeared with age (Figure 2B).

**Age-related ICH and macro-angiopathy are consequences of developmental defects**

To distinguish between potentially distinct roles for COL4A1 in cerebrovascular development
and maintenance we engineered a conditional \textit{Col4a1} mutation by flanking exon 41 with \textit{LoxP} sites (\textit{Col4a1}^{Flex41}). This allele recreates the \textit{Col4a1}^{dext41} mutation in a CRE-dependent manner (Supplemental Figure 4). We crossed \textit{Col4a1}^{+/Flex41} mice to the inducible, ubiquitous CRE strain \textit{R26-Cre}^{ER} \textsuperscript{21}, injected tamoxifen at birth, 1 week or 3 weeks, validated CRE activation and quantified retinal branching and ICHs (Figure 3 and Supplemental Figure 5). In 8-month-old \textit{R26-Cre}^{ER}; \textit{Col4a1}^{+/Flex41} mice, ICHs were more severe in mice that started to express mutant collagen at birth than at 1 week and were absent in mice that started to express mutant collagen at 3 weeks. Pathology in neither group was as severe as \textit{Col4a1}^{+/dext41} and none of the mice had porencephaly or macro-angiopathy. These data demonstrate that age-related, recurrent ICHs and macro-angiopathy do not occur in the absence of pre- and post-natal developmental defects. To refine the timing of pathogenesis we induced the \textit{Col4a1} mutation at E10.5 or E14.5 and quantified ICHs at 1 month. ICHs were more severe in mice induced at E10.5 than at E14.5. Again, neither group was as severe as \textit{Col4a1}^{+/dext41}, however, controls revealed reduced recombination efficiency with embryonic induction of mutant \textit{Col4a1} (Supplemental Figure 5).

Together, these data demonstrate that the effects of mutant \textit{COL4A1} require expression during embryogenesis and the early postnatal period in order to cause progressive, recurrent ICHs and age-related macro-angiopathy.

\textbf{ICH modulation by environmental and genetic factors.}

We sought ways to reduce the severity of progressive ICH. In the previous experiment, tamoxifen injection during pregnancy compromised natural birth and necessitated surgical delivery. A beneficial effect of surgical delivery was previously proposed but not quantified\textsuperscript{27}. We found that tamoxifen-treated, surgically delivered \textit{Col4a1}^{+/dext41} mice had less ICHs than non-treated, naturally born \textit{Col4a1}^{+/dext41} mice (Figure 4A). Next, we quantified the impacts of
other modifiable risk factors that have been anecdotally associated with ICH in patients with COL4A1 or COL4A2 mutations including physical exertion\textsuperscript{28-30}, and anticoagulant administration\textsuperscript{5, 6, 27, 31}. We found that exercise increased ICH severity (\textbf{Figure 4B}) and anticoagulants provoked fatal hemorrhages within just seven days of use (\textbf{Figure 4C}). Together, these data establish vaginal delivery, exercise and anticoagulants as modifiable risk factors that increase ICH severity in \textit{Col4a1}\textsuperscript{+/Dex41} mice.

Genetic factors may also influence clinical heterogeneity among patients with \textit{COL4A1} and \textit{COL4A2} mutations\textsuperscript{32, 33} and can reveal pathogenic mechanisms and interventional approaches. We compared ICH severity in 1) mice with different mutations on the same genetic background and 2) mice with the same mutation on different genetic backgrounds. The allelic series comprised \textit{Col4a1}\textsuperscript{Dex41}, seven glycine mutations in the triple-helical domain (six in \textit{COL4A1}, one in \textit{COL4A2}) and one mutation in the \textit{COL4A1} NC1 domain (\textbf{Figure 5A})\textsuperscript{18, 20}. We backcrossed each strain to C57BL/6J (B6) mice, aged cohorts for 7.5-9.5 months (called 8-month cohort) and compared porencephaly, ICH and macro-angiopathy. We identified distinct classes of mutations and three potential genotype-phenotype correlations (\textbf{Figure 5A} and \textbf{Supplemental Figure 6}). First, there appears to be a ‘class effect’ whereby \textit{Col4a1}\textsuperscript{Dex41} is more severe than missense mutations. Second is a domain effect whereby the NC1 domain mutation is milder than the triple-helical domain mutations. Third, for mutations within the triple-helical domain, there was a position effect whereby mutations nearer the carboxy terminus were more severe than mutations nearer the amino terminus. These data establish the powerful effects of allelic heterogeneity on ICH severity and suggest that there are class, domain and position effects of different alleles that resemble effects observed in other types of collagens\textsuperscript{19, 34-36}. Next, we tested the effect of genetic context on ICH severity. We crossed B6 \textit{Col4a1}\textsuperscript{+/Dex41} mice to CAST/EiJ
We compared ICH severity among Col4a1+/Δex41 mice and found that CASTB6F1 genetic context significantly suppressed ICH but 129B6F1 did not (Figure 5B). CASTB6F1 also reduced porencephaly penetrance, and delayed macro-angiopathy onset (Supplemental Figure 7). The effect was not allele- or gene-specific as CASTB6F1 also significantly suppressed ICH in Col4a1+/G1344D and Col4a2+/G646D mice (Figure 5C). Surprisingly, there were neither allelic nor genetic context effects on retinal or cerebral blood vessel defects (Figure 5D). The observations of allelic and genetic-context effects on ICH - but not on the vascular patterning defects - suggest that processes in addition to defective angiogenesis and vascular patterning may be required for ICH progression.

Pathogenic collagen accumulation in vascular endothelial cells and pericytes

Heterotrimers that incorporate mutant COL4A1 or COL4A2 tend to accumulate within cells at the expense of secretion. Because ICH severity correlates with intracellular accumulation in the allelic series18, we hypothesized that CASTB6F1 suppression of ICH might occur by reducing intracellular COL4A1. We compared intracellular and extracellular COL4A1 in primary fibroblasts and found that Col4a1+/Δex41 caused significantly increased intracellular COL4A1 in B6 but not CASTB6F1 cells (Figure 6A). Moreover, the CASTB6F1 background normalized intracellular without increasing extracellular COL4A1 levels – a distinction that was also striking in vivo. Blood vessels from B6 Col4a1+/Δex41 animals had punctuate intracellular COL4 labeling and less intense labeling of the vascular basement membrane than Col4a1+/+ mice. CASTB6F1 Col4a1+/Δex41 vessels do not show intracellular labeling yet still lacked intense labeling of the basement membrane (Figure 6B). Thus, mutant mice from both backgrounds have reduced extracellular COL4A1 yet only B6 mice have significant intracellular accumulation and severe
ICH. Importantly, these data dissect the potential roles of intracellular accumulation and extracellular deficiency and suggest that chronic intracellular accumulation may cause ICH in the context of developmentally abnormal vessels.

To test the relative effects of the different cell types of the neurovascular unit, we conditionally expressed mutant Col4a1 in vascular endothelial cells (VECs), pericytes or astrocytes using Tie2-Cre\textsuperscript{22}, Pdgfrb-Cre\textsuperscript{23} or Gfap-Cre\textsuperscript{24} transgenic mice respectively (Figure 6C). We validated these lines (Supplemental Figure 8A) and quantified ICH at 1 and 8 months. Specific expression of mutant Col4a1 only in astrocytes did not overall significantly affect retinal branching and gave very mild ICHs in only 3 out of 8 old animals (Figure 6D and E). Expression in VECs– or pericytes–only was sufficient to phenocopy excess retinal vascular branching of Col4a1\textsuperscript{+/Flex41} (Figure 6D), caused fully penetrant ICH (Figure 6E) and incompletely penetrant porencephaly and macro-angiopathy (Supplemental Figure 8B). However neither strain demonstrated ICH as severe as that in Col4a1\textsuperscript{+/Flex41} mice. Interestingly, when we tested E16.5 embryos, ICH was greater in Tie2-Cre; Col4a1\textsuperscript{+/Flex41} compared to Pdgfrb-Cre; Col4a1\textsuperscript{+/Flex41} mice and the postnatal viability of Tie2-Cre; Col4a1\textsuperscript{+/Flex41} mice was much lower (27\% compared to 100\% for Pdgfrb-Cre; Col4a1\textsuperscript{+/Flex41} mice) (Supplemental Figure 4D). Therefore, the most severely affected Tie2-Cre; Col4a1\textsuperscript{+/Flex41} mice may be underrepresented in postnatal analyses leading to an underestimate of the relative role of VECs in the pathogenesis. These data suggest that both VECs and pericytes contribute to vascular defects and that VECs may play a relatively larger role.

The results from CASTB6F1 mice suggest that reducing intracellular accumulation may suppress ICH, and results from the inducible mutation indicate that postnatal intervention may be effective. Sodium 4-phenylbutyrate (4PBA), an FDA-approved chemical chaperone, has been
used in several models of disorders due to protein misfolding and we recently showed that its properties extend to COL4A1 in vitro. To test our hypothesis in vivo, we treated pups with 4PBA from birth to weaning age and analyzed retinal vasculature and ICH at 1 month. Treatment had no effect on vessel branching, however, there was decreased intracellular accumulation and qualitatively more uniform labeling of vascular basement membranes. Importantly, compared to untreated Col4a1+/Δex41 mice, mutant animals treated with 4PBA had significantly less severe ICH (Figure 7). These data are the first to show therapeutic prevention of Col4a1-related ICH in vivo and support the hypothesis that promoting protein folding might also prevent ICH in patients with COL4A1 and COL4A2 mutations.

Discussion

Col4a1 and Col4a2 mutant mice model important aspects of human disease. Embryonic germinal matrix hemorrhages cause porencephaly and early small vessel disease presents as microbleeds throughout the brain. Later, recurrent ICHs and age-related macro-angiopathy occur mainly in the basal ganglia. Importantly, our data bring new insights into the disease biology and suggest that two pathogenic mechanisms are necessary to cause ICH. First, we showed that Col4a1 and Col4a2 mutations cause abnormal angiogenesis. The fact that mice which start to express mutant collagen after the completion of vascular development do not suffer from ICH suggests that abnormal angiogenesis is required to trigger hemorrhage. Second, we showed that Col4a1 mutation causes increased intracellular and decreased extracellular collagen. The fact that ICH severity associates with the level of intracellular accumulation but not with extracellular deficiency (Figures 5B and 6A and B) suggests that the intracellular accumulation is a key molecular mechanism in the progression to vasculature rupture. A similar observation was
reported in human cells cultured from an ICH patient with a COL4A2 mutation and his unaffected father who also carried the mutation. The fact that the blood-brain-barrier of the abnormally developed vessels is not generally compromised also supports this hypothesis, suggesting that chronic intracellular accumulation could reach locally toxic thresholds and provoke focal ICH. Interestingly, we show that abnormal angiogenesis is independent from the level of intracellular collagen accumulation, suggesting that extracellular insults might underlie abnormal vascular development. To support this hypothesis, it would be interesting to investigate the COL4A1/COL4A2 network in the vascular basement membrane. Indeed, this network has been shown to interact directly with several signaling pathways involved in angiogenesis such as TGFβ/BMP signaling, Notch signaling and integrin signaling and Arresten, a proteolytic fragment of COL4A1 has anti-angiogenic properties. Although further understanding the roles of COL4A1 and COL4A2 in angiogenesis is compelling, developmental defects remain challenging to target therapeutically. Thus, we showed that targeting intracellular collagen accumulation using 4PBA, even after birth, successfully decreases ICH severity in vivo. These data support that mechanism-based treatments, such as chemical chaperones, might also prevent ICH in patients with COL4A1 and COL4A2 mutations.

We investigated a clinically relevant series of Col4a1 and Col4a2 mutations and discovered important allelic effects that resemble those identified for other type of collagens. These data have implications for patient screening and for functionally validating mutations that are identified by genetic testing. We show that mutation class, domain and position all influence ICH severity and correlate with intracellular accumulation of heterotrimers. Mutations that are near the amino terminus of the triple-helical domain may cause only mild intracellular collagen accumulation and therefore be overlooked by functional assays that
measure relative levels of intracellular collagen resulting in false negatives (e.g. \( \text{Col4a1}^{+/-G394V} \))\textsuperscript{18}. Therefore position effects should be considered when functionally testing putative mutations and the incidence of \( \text{COL4A1} \) and \( \text{COL4A2} \) mutations may be higher than current estimates.

Interestingly, despite differences in stoichiometric contributions to heterotrimer composition, positionally matched mutations in \( \text{Col4a1} \) and \( \text{Col4a2} \) caused similar ICH severity, which underscores the importance of analyzing both genes when genetically screening patients.

Importantly, our data suggests that the mechanism by which \( \text{COL4A1} \) and \( \text{COL4A2} \) mutations cause ICH might be specific to this phenotype, which may have important implications for patient prognosis and treatment. First, 129B6F1 genetic context modified ocular dysgenesis\textsuperscript{32} but not ICH. Second, in the allelic series, ICH severity correlates with levels of intracellular accumulation whereas myopathy does not\textsuperscript{18}. This is illustrated by \( \text{Col4a1}^{G394V} \), which is among the mutations causing the most severe myopathy, but the least severe ICH.

HANAC (hereditary angiopathy, nephropathy, aneurysms, and cramps) describes a sub-set of patients with myopathy, relatively mild cerebrovascular disease, and whose mutations cluster near integrin binding domains in the amino-terminal quarter of \( \text{COL4A1} \). Our data (Figure 5A and ref.\textsuperscript{18}) suggest a molecular explanation for HANAC whereby mutations in or near integrin binding domains lead to myopathy, and because these domains are near the amino terminus, the mutations cause only mild intracellular collagen accumulation and relatively mild ICH.

Mechanistic heterogeneity has important implications for targeted therapies and patient treatment. These results suggest that pharmacologic interventions that prevent ICH might not be efficacious for other phenotypes and that comprehensive patient treatment might require distinct approaches for distinct pathologies.

We have identified vaginal delivery, acute exercise and anticoagulant use as modifiable
environmental risk factors that exacerbate ICH severity in Col4a1+/Δex41 mice. Anticoagulation is a highly effective treatment for prevention of thromboembolic stroke. However, our results and reports of patients with COL4A1 or COL4A2 mutations suffering from hemorrhagic stroke while taking anticoagulant medication suggest that the risks of antithrombotic therapy may be judged to outweigh its benefits5, 6, 27, 31. These decisions will need to be measured against the increased risk for ICH. Similarly, Col4a1 mutations are not associated with hypertension27, 44, however, acute exercise in mice induced ICH and has been associated with hemorrhagic events in patients28-30. These data are important for patients with COL4A1 and COL4A2 mutations who are considering the beneficial or detrimental consequences of physical exercise. Although Cesarean delivery will not reduce or prevent embryonic ICH or porencephaly, our data demonstrate that Cesarean delivery of genetically at-risk individuals may reduce perinatal ICH. Because of the exacerbating effects of acute exercise, Cesarean delivery may also be warranted when the mother carries the mutation.

Altogether, we used an allelic series, genetic modification and a conditionally expressed Col4a1 mutation to distinguish the relative impacts of intracellular accumulation from extracellular COL4A1 deficiency, dissect cell-type specific contributions, and define a window for potential therapeutic intervention. Our data suggest that intracellular collagen accumulation is responsible for ICH progression. Thus, promoting either heterotrimer degradation or secretion may be viable approaches to reduce ICH severity. Importantly, we show that 4PBA, a readily available small molecule with chaperone properties, reduced ICH severity in vivo. Together this work demonstrates efficacy of controlling modifiable environmental risk factors and application of a mechanism-based therapy to prevent ICH caused by COL4A1 mutations.
Acknowledgments: We thank J. Rosand, R. Libby, R. Daneman, P. Yurchenco and members of the Gould lab for critical reviews of the manuscript.

Funding Sources: This study was funded by the American Heart Association (AHA), National Institutes of Heath (NS083830) and That Man May See (D.B.G.). Support was also provided by an AHA postdoctoral fellowship (M.J.) and by a core grant from the National Eye Institute (EY02162), a Research To Prevent Blindness Unrestricted Grant (UCSF Department of Ophthalmology), the Sandler Program in Basic Sciences (D.B.G.) and the Karl Kirchgessner Foundation (D.B.G.).

Conflict of Interest Disclosures: None.

References:


**Figure Legends:**

**Figure 1.** Col4a1 mutation causes abnormal cerebral and retinal vascular development. (A) At embryonic day (E) 10.5 Col4a1+/−ex41 mice have irregularly shaped, enlarged blood vessels (calculated in branchial arches using CD31 and Collagen type IV (COL4) labeling, scale bar: 100 μm) and intracerebral hemorrhages (arrow). (B) At E12.5 Col4a1+/−ex41 mice have abnormally tortuous vessels with increased density (calculated in hindbrain flatmounts using CD31 labeling, scale bar: 100 μm) (C) In mutant animals, retinal blood vessels are tortuous, arteries (A) and veins (V) cross each other and there is excess branching in the main veins (5≤n≤16, pair-wise comparisons per age, scale bar: 500 μm). (D) Intracardiac perfusion of biotin revealed that adult mutant animals have tortuous cerebral blood vessels without compromised blood-brain-barrier (scale bar: 100 μm). Data are reported as mean + standard deviation and * indicates p<0.05 compared to Col4a1+/+ by Student’s *t*-test.

**Figure 2.** Col4a1 mutation causes small vessel disease, hemorrhagic stroke and macroangiopathy. (A) Col4a1+/−ex41 mice have porencephaly (penetrance: 80%) and intracerebral
hemorrhages (penetrance: 100%) quantified using Prussian blue staining of serial coronal brain sections (scale bar: 1 mm). Data are reported as mean ± standard deviation. **(B)** Macroangiopathy with vessel wall thickening, fibrosis and thrombosis advanced with age. Trichrome staining shows collagen deposition (blue) and fibrin accumulation (red) in affected blood vessels (scale bar: 100 μm). No Col4a1+/+ mice had porencephaly, intracerebral hemorrhage or macroangiopathy (n=32).

**Figure 3.** Mutant Col4a1 causes cerebrovascular disease when expressed during vascular development. **(A)** Col4a1+/Flex41 conditional mutant mice were crossed to R26-CreER ubiquitous inducible CRE mice and the CRE recombinase was activated at different time points during or after vascular development by tamoxifen injections. **(B)** Quantification of retinal vessels revealed excess branching in mice that started to express mutant COL4A1 at birth but not at 1- or 3-weeks. n.s.: p>0.05, *: p<0.05 compared to Flex41 only (Col4a1+/Flex41; R26-CreER/-) mice by Student’s t-test. **(C)** ICH quantification at 1 or 8 months of age shows that ICH severity increases with earlier age of expression of the collagen mutation. *: p<0.05 by Kruskal-Wallis test followed by Dunn’s post-test. Data are reported as mean ± standard deviation.

**Figure 4.** Environmental factors contribute to Col4a1 mutation expressivity. Intracerebral hemorrhage quantification in Col4a1+/Flex41 mice: **(A)** after vaginal delivery or Cesarean section, **(B)** without or with five sessions of five one-minute sprints on a treadmill, **(C)** without or with 7 days of Warfarin anticoagulant administration. Data are reported as mean ± standard deviation.

**Figure 5.** Allelic heterogeneity and genetic context contribute to the expressivity of Col4a1 and
Col4a2 mutations. (A) Intracerebral hemorrhage (ICH) quantification in 8-month-old mice with different mutations but the same genetic background, C57BL/6J (B6), demonstrates that allelic heterogeneity influences ICH severity. *: p<0.05 by Kruskal-Wallis test followed by Dunn’s post-test. (B) ICH quantification in 8-month-old mice with the same Col4a1^{del41} mutation but different genetic contexts shows that genetic background influences ICH severity. A cross for one generation to CAST/EiJ (CAST), but not 129S6/SvEvTac (129) mice was sufficient to reduce ICH severity compared to Col4a1^{+/del41} mice on a B6 background. *: p<0.05 by ANOVA followed by Tukey post-test. (C) CAST suppression of ICH was consistent across different mutations, however, (D) did not extend to prevention of vascular tortuosity and excess branching (COL4 labeling in the retina, CD31 labeling in the brain, scale bars: 50 μm). In (C) and (D) n.s. indicates p>0.05 and ** indicates p<0.01 by Student’s t-test. Data are reported as mean ± (A, B and C) or + (D) standard deviation.

Figure 6. Intracerebral hemorrhages associate with intracellular COL4A1 accumulation in vascular endothelial cells and pericytes but not with extracellular deficiency. (A) Immunolabeling and Western blot show that intracellular COL4A1 in Col4a1^{+/del41} cells from B6 mice is greatly reduced in cells from CASTB6F1 mice but without an obvious increase in extracellular COL4A1 (C: cell lysate, M: conditioned medium, Laminin and Tubulin are controls for secreted and intracellular proteins, respectively). Results constitute representative examples from twelve independent biological replicates obtained from three independent experiments. (B) Immunolabeling of Col4a1^{+/del41} retinal vessels shows strong intracellular collagen type IV (COL4) in B6 but not CASTB6F1 mice. (C) Col4a1^{+/Flex41} mice were crossed to Tie2-Cre, Pdgfrb-Cre or Gfap-Cre strains for mutant Col4a1 conditional expression in vascular endothelial
cells (VECs), pericytes or astrocytes respectively. (D) Retinal vessel quantification revealed excess branching with mutant expression in VECs and pericytes but not astrocytes. n.s.: p>0.05, *: p<0.05 compared to Flex41-only mice (Col4a1+/Flex41; Cre+/−) by Student’s t-test. (E) Intracerebral hemorrhage (ICH) quantification demonstrated that mutant Col4a1 expression in VECs or pericytes is sufficient to cause ICH but that neither cell-type alone phenocopies Col4a1+/Δex41. Conditional expression of mutant Col4a1 in astrocytes caused very mild ICHs in only three 8-month-old animals. *: p<0.05 by Kruskal-Wallis test followed by Dunn’s post-test. Scale bars: 50 μm. Data are reported as mean + (D) or ± (E) standard deviation.

Figure 7. Treatment with chemical chaperone sodium 4-phenylbutyrate (4PBA) reduces intracerebral hemorrhage severity in vivo. Col4a1+/+Δex41 mice treated from birth to 3 weeks with sodium 4-phenylbutyrate (4PBA) had similar levels of retinal vessel branching (A) but less severe intracerebral hemorrhages (ICHs) (B) compared to untreated Col4a1+/Δex41 mice. n.s.: p>0.05 by Student’s t-test. Immunolabeled vessels showed less intracellular and more extracellular collagen type IV (COL4) in the treated Col4a1+/+Δex41 mouse with the least, compared to greatest, ICH severity. Scale bars: 50 μm. Data are reported as mean + (A) or ± (B) standard deviation.
Figure 1
**Figure 2**

(A) *Col4a1Δex41* brains
- Porencephaly
- Intracerebral hemorrhages (Prussian Blue staining)

(B) *Col4a1Δex41* brains
- Fibrosis
- Thrombosis

Bar graph showing the percentage of affected mice at different time points (1 month, 3 months, 8 months, > 1 year) with categories for macro-angiopathy:
- Both
- Fibrosis
- Thrombosis
- None

Trichrome staining image
Figure 4

A. Cesarean section

- Brain area containing hemosiderin
- At 1 month
- Vaginal delivery
- Cesarean section

B. Acute exercise (Treadmill)

- Brain area containing hemosiderin
- At 3 months
- No exercise
- Acute exercise

C. Anti-coagulant medication

- Brain area containing hemosiderin
- At 3 months
- No treatment
- Warfarin

+ 2 with fatal ICH

p = 0.02
p = 0.0004
p = 0.7
Figure 5
Figure 7

Panel A: Retinal vasculature
- No treat (wild type) vs. 4PBA
- +/- vs. +/-Δex41
- Branch points per primary vein comparison

Panel B: Intracerebral hemorrhages
- Brain area (%) containing hemosiderin
- No treat vs. 4PBA
- +/-Δex41
- p = 0.02

Images:
- Retinas
- Brains
- COL4, CD31, DAPI
Molecular and Genetic Analysis of Collagen Type IV Mutant Mouse Models of Spontaneous Intracerebral Hemorrhage Identify Mechanisms for Stroke Prevention
Marion Jeanne, Jeff Jorgensen and Douglas B. Gould

Circulation. published online March 9, 2015:

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/early/2015/03/09/CIRCULATIONAHA.114.013395

Data Supplement (unedited) at:
http://circ.ahajournals.org/content/suppl/2015/03/09/CIRCULATIONAHA.114.013395.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org/subscriptions/
Supplemental Figure 1: Col4a1Δex41 causes embryonic growth retardation, reduced viability and multifocal hemorrhages (A) Growth retardation is observed in Col4a1Δex41Δex41 mutants as early as embryonic day (E) 9.5 and is more pronounced in homozygous Col4a1Δex41/Δex41 mutants, which do not survive after mid-gestation. (B) In backcross matings, mutant embryos are represented at expected ratios of 1:1 until birth when Col4a1Δex41Δex41 mice have reduced viability (n: number of animals for each time point). (C) At birth (postnatal day 0: P0), Col4a1Δex41Δex41 pups have multi-focal subcutaneous hematomas and intraparenchymal hemorrhages.
Supplemental Figure 2: Blood-brain-barrier and blood-retina-barrier are not compromised in Col4a1^{+/Δex41} animals (A) As a positive control for the experiment presented in Figure 1 (D), we show that biotin diffuses from the blood vessel into the liver (bottom) whereas it stays inside the cerebral vasculature (top) because of the presence of the blood-brain-barrier in a Col4a1^{+/+} mouse (B) In Col4a1^{+/Δex41} mice, intracardiac perfusion of biotin revealed that the blood-brain-barrier is intact (unaffected blood vessel) until the vasculature ruptures, leading to hemorrhage and leakage of biotin in the surrounding parenchyma (hemorrhagic blood vessel) (C) Intra-peritoneal injection of sodium fluorescein reveals no general leakage of the Col4a1^{+/Δex41} blood-retina-barrier on ocular fundus examination. (D) Blood-brain-barrier proteins such as zona occludens protein 1 (ZO-1) and Claudin 5 (CLDN5) (labeled in green) are expressed in Col4a1^{+/Δex41} cerebral blood vessels (labeled with CD31, red) as early as E14.5.
Supplemental Figure 3: Col4a1<sup>+/Δex41</sup> mice have anemia. Blood analysis at 4 months shows decreased number of red blood cells and abnormally low hemoglobin level in Col4a1<sup>+/Δex41</sup> (n=5) compared to Col4a1<sup>+/+</sup> mice (n=9). Data are reported as mean + standard deviation. *: p<0.05 compared to Col4a1<sup>+/+</sup> mice by Student’s t-test.
**Supplemental Figure 4:** The Col4a1<sup>Δex41</sup> conditional mutant allele in presence of active CRE recombinase mimics the Col4a1<sup>Δex41</sup> mutation (A) The Col4a1<sup>Δex41</sup> conditional mutant allele has exon 41 flanked by LoxP sites. In the presence of active CRE recombinase, exon 41 is removed, mimicking pathogenic effects of the Col4a1<sup>Δex41</sup> mutation such as (B) intracellular accumulation of collagen in the endoplasmic reticulum (ER) (MEFs: primary mouse embryonic fibroblasts, HSP47: ER marker). (C) Compared to littermate controls that did not have hemorrhage, double heterozygous Col4a1<sup>Δex41</sup>; Tie2-Cre<sup>CRE/–</sup> (endothelial-specific expression of CRE) P0 pups showed perinatal multifocal intracerebral hemorrhage (ICH). cDNA from whole brain amplified with primers in Col4a1 exons 40 and 42 detected expression of transcripts missing exon 41 (51 nucleotides) in Col4a1<sup>+/Flex41</sup> mice when CRE is present (lower band). (D) Average number of ICHs per brain section in E16.5 embryos. Col4a1<sup>Δex41</sup>; Actb-Cre<sup>CRE/–</sup> embryos, expressing CRE recombinase ubiquitously have as many ICH as Col4a1<sup>Δex41</sup> embryos. The survival rate at weaning age is indicated (%). Data are reported as mean ± standard deviation.
Supplemental Figure 5: Tamoxifen induces ubiquitous CRE activation when injected after birth, but only partial CRE activation when injected during gestation (A) We evaluated the efficiency of CRE activation by tamoxifen using the TdTomato reporter mouse strain. Postnatal tamoxifen injection achieved ostensibly complete recombination whereas prenatal tamoxifen injection did not (TdTomato in red, CD31 in green) (B) Quantification of retinal vein branch points showed excess branching when tamoxifen was delivered before or at birth but not after one week (when retinal vascular development is completed) confirming that tamoxifen delivery and mutant Col4a1 induction was successful (9≤n≤36). n.s.: p>0.05, *: p<0.05 compared to Flex41 only (Col4a1+/Flex41, R26CreER−/−) mice by Student’s t-test. (C) Intracerebral hemorrhage (ICH) quantification of brains from 1-month old mice showed that mutant Col4a1 induction at E10.5 or E14.5 caused ICH and that earlier induction led to more ICH. Tamoxifen administration compromised natural birth so all liters were surgically delivered (C sect). The observation that E10.5 induction did not phenocopy Col4a1+/Δex41 mice likely reflects the reduced recombination efficiency shown in A. Data are reported as mean + (B) or ± (C) standard deviation.

Supplemental Figure 6: Porencephaly and macro-angiopathy in an allelic series of Col4a1 and Col4a2 mutations. We analyzed 27 regularly spaced coronal cryo-sections per brain (n=5-7 mice per genotype) to determine the frequencies of porencephaly and macro-angiopathy in mice from the allelic series.
Supplemental Figure 7: CASTB6F1 genetic context prevents or delays cerebrovascular disease caused by Col4a1Δex41 mutation. The penetrance of porencephaly in Col4a1Δex41 mice was reduced by CASTB6F1 but not 129B6F1 genetic context. CASTB6F1 also prevents or delays macro-angiopathy in Col4a1Δex41 mice. C57BL/6J (B6), CAST/EiJ (CAST), 129S6/SvEvTac (129) (n: number of animals in each cohort).

Supplemental Figure 8: Cell type specific expression of mutant COL4A1 (A) Cell type specific CRE mouse strains were crossed with a TdTomato reporter strain to show the specificity of the CRE expression: in astrocytes, in pericytes and in vascular endothelial cells (VECs) for Gfap-Cre, Pdgfrb-Cre and Tie2-Cre respectively (CD31 labeled the VECs in green, TdTomato is red in cells expressing the CRE, brain sections of embryonic day 12.5 embryos) (B) Porencephaly and macro-angiopathy penetrance were quantified using serial coronal brain sections (n: number of animals in each cohort).